DNLI - Denali Market Cap to Sales Volume
The P/S ratio dynamics for Denali Therapeutics (DNLI) on the GURU.Markets chart are based on the outsourcing of trials via external contractors, with the 140.10 value reflecting the current metric. Growth is driven by partnerships with pharma behemoths to overcome blood-brain barriers, while the success of the scientific pipeline is guaranteed by strict adherence to cold chain logistics for biomaterials.
Analytical breakdowns for Denali Therapeutics Inc (DNLI)
- share price and consensus valuation forecast:
- market capitalization statistics:
- book capitalization information:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Denali Therapeutics|DNLI - Long-Term Debt to Capital|Short-Term Debt to Capital Denali Corp|DNLI - Company Debts|Debts to Book Capitalization Ratio Denali Therapeutics Inc|DNLI - Company Long-Term Debts|Short-Term Debt Denali Therapeutics|Quick Ratio denalitherapeutics.com
- earnings and valuation multiples information:
DNLI - Net Income|Future Net Profit Denali Therapeutics|DNLI - P/E Multiple|Market Cap to Projected Earnings Denali|DNLI - PEG Multiple|Enterprise Value to EBITDA Ratio Denali Therapeutics Inc|DNLI - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Denali Therapeutics|DNLI - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last 12 months denalitherapeutics.com|DNLI - Earnings per share growth in current year|Projected earnings per share growth rate for next year Denali Therapeutics
- issuer revenue and sales details:
Fundamental company analysis:denalitherapeutics.com - DNLI
The P/S multiple reflects the market value of a business relative to its annual revenue, allowing for an assessment of the asset's overvaluation by comparing current capitalization with historical extremes. By analyzing the price-to-sales multiple, an investor can determine the fairness of the valuation of Denali Therapeutics (DNLI), taking into account the potential of the blood-brain barrier drug delivery platform and expected payments from strategic partners.
Competing companies
BIIB (biogen.com) - Market Capitalization-to-Revenue Ratio|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Cap to Sales Volume RGC (Regencell Bioscience Ltd)|Axsome Therapeutics Inc - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|XENE: P/S Multiple|Price to Sales vikingtherapeutics.com (VKTX)|Price-to-Revenue Ratio Supernus|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple HRMY|P/S Multiple Biohaven Corp (BHVN)|Price-to-Revenue Ratio Amylyx Pharmaceuticals AMLX|TRVI (trevitherapeutics.com) - Price-to-Sales Ratio|Praxis Precision Medicines, Inc. - P/S Multiple|Price to Sales Anavex|CBLL (CeriBell Corp) - Market Cap to Revenue|Prothena Corp (PRTA) - P/S Multiple|Market Cap to Revenue ALEC|ANNX (annexonbio.com) - Market Cap to Sales Volume|P/S Multiple OMER|Price-to-Revenue Coefficient Neurogene Inc|P/S Multiple ACIU (AC Immune Corp)|VYGR - Market Cap to Revenue|NMRA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient scilexholding.com SCLX|TVGN: P/S Multiple|Market Cap to Revenue Ratio ACOG|Price-to-Revenue Ratio Cognition Therapeutics, Inc.|Market Cap to Revenue Ratio IKT (Inhibikase Pharma)|Price-to-Revenue Ratio Cassava Sciences, Inc. (SAVA)|Price-to-Revenue Ratio ASRT (assertiotx.com)|P/S Multiple COYA (Coya Therapeutics)|Price-to-Revenue Coefficient VistaGen Therapeutics, Inc. (VTGN)|OVID - Price-to-Revenue Ratio|ABOS (Acumen Pharmaceuticals, Inc) - Market Cap to Revenue Ratio|CRVO: P/S Multiple|Price to Sales Alterity Therapeutics Limited (ATHE)|Market Cap to Revenue CLNN|P/S Multiple PepGen Corp|Price-to-Revenue Ratio Jupiter Neurosciences (JUNS)|RLMD (Relmada Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Annovis Bio, Inc. ANVS|Grace Therapeutics Inc (GRCE) - Price to Sales|Firefly Neuroscience - P/S Multiple|KLTO (Klotho Neurosciences Inc) - Market Cap to Revenue Ratio|NRSN: P/S Multiple|Price to Sales Reviva Pharmaceuticals, Inc. (RVPH)|Price-to-Revenue Ratio MetaVia Inc.|Market Cap to Revenue Ratio NRXS (neuraxis.com)|P/S Multiple HSDT|P/S Multiple passagebio.com (PASG)|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|Minerva - Price-to-Revenue Ratio|Athira Pharma, Inc. - P/S Multiple|Price-to-Revenue Coefficient addextherapeutics.com ADXN|ALZN (alzamend.com) - Market Cap to Revenue|Cyclerion Therapeutics, Inc. - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue PTIX|KTTA (Pasithea) - Market Cap to Sales Volume|P/S Multiple CRGT|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|Cara Therapeutics Inc. (CARA) - Price to Sales|CHRO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ELYM (Eliem Therapeutics)|ITCI: P/S Multiple|longboardpharma.com (LBPH) - P/S Multiple|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|NKGen Biotech Inc - Price-to-Sales Ratio|P/S Multiple NRBO|SAGE - Price to Sales|Synaptogenix, Inc. - Market Cap to Revenue|P/S Multiple trevena.com TRVN|VIGL: Market Cap to Revenue|anewmeds.com - Market Cap to Sales Volume|CERE: P/S Multiple
